Fertility and Sterility
Volume 92, Issue 4 , Pages 1360-1365 , October 2009

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase

  • Michael von Wolff, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany
    • Corresponding Author InformationReprint requests: Michael von Wolff, Department of Gynecologic Endocrinology and Reproductive Medicine, University of Heidelberg, Voßstraße 9, 69115 Heidelberg, Germany (FAX: 49-6221-565356).
    • ,
  • Christian J. Thaler, M.D.

      Affiliations

    • Gynecologic Endocrinology and Reproductive Medicine, Women's Hospital, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Grosshadern, Germany
    • ,
  • Torsten Frambach, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Wuerzburg, Wuerzburg, Germany
    • ,
  • Cosima Zeeb, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproduction, Women's Hospital of St. Gallen, St. Gallen, Switzerland
    • ,
  • Barbara Lawrenz, M.D.

      Affiliations

    • Women's Hospital, University of Tuebingen, Tuebingen, Germany
    • ,
  • Roxana M. Popovici, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany
    • ,
  • Thomas Strowitzki, M.D.

      Affiliations

    • Department of Gynecologic Endocrinology and Reproductive Medicine, Women's University Hospital, University of Heidelberg, Heidelberg, Germany

Received 2 April 2008 ,Revised 2 August 2008 ,Accepted 7 August 2008.

References 

  1. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999;86:697–709
  2. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol. 2002;20:1880–1889
  3. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–2931
  4. Madrigrano A, Westphal L, Wapnir I. Egg retrieval with cryopreservation does not delay breast cancer treatment. Am J Surg. 2007;194:477–481
  5. Fertiprotekt. Network for fertility preservation before chemo- and radiotherapy. Available at: http://www.fertiprotekt.eu. Accessed 15 March 2008.
  6. Anderson RA, Kinniburgh D, Baird DT. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod. 1999;14:2665–2668
  7. Fridén BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand. 2005;84:812–816
  8. Humaidan P, Bungum L, Bungum M, Hald F, Agerholm I, Blaabjerg J, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online. 2005;11:679–684
  9. Menezo Y. Cryopreservation of IVF embryos: which stage?. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl 1):S28–S32
  10. Deutsches IVF-Register. Available at: http://www.deutsches-ivf-register.de. Accessed 15 March 2008.
  11. Niswender GD, Juengel JL, Silva PJ, Rollyson MK, McIntush EW. Mechanisms controlling the function and life span of the corpus luteum. Physiol Rev. 2000;80:1–29
  12. Zeleznik AJ. In vivo responses of the primate corpus luteum to luteinizing hormone and chorionic gonadotropin. Proc Natl Acad Sci U S A. 1998;95:11002–11007
  13. Del Canto F, Sierralta W, Kohen P, Muñoz A, Strauss JF, Devoto L. Features of natural and gonadotropin-releasing hormone antagonist-induced corpus luteum regression and effects of in vivo human chorionic gonadotropin. J Clin Endocrinol Metab. 2007;92:4436–4443
  14. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab. 2007;92:2197–2200

 M.v.W. has nothing to disclose. C.T. has nothing to disclose. T.F. has nothing to disclose. C.Z. has nothing to disclose. B.L. has nothing to disclose. R.P. has nothing to disclose. T.S. has nothing to disclose.

PII: S0015-0282(08)03367-0

doi: 10.1016/j.fertnstert.2008.08.011

Fertility and Sterility
Volume 92, Issue 4 , Pages 1360-1365 , October 2009

Article Tools

* Image Usage & Resolution